This week on The Wealthing Podcast, Alicia is joined by Jason Bock, CEO of CTMC, for an inspiring look inside the front lines of cancer treatment innovation at MD Anderson Cancer Center. Jason details the revolutionary shift toward personalized, single-dose cell therapies that engineer a patient's own T-cells to target and eliminate cancer. This cutting-edge approach represents a fundamental pivot in medicine—moving away from chronic, ongoing disease management and toward treatments designed with true curative intent, allowing individuals to completely reclaim their lives from a cancer diagnosis.

The conversation follows Jason's personal career evolution within biotech and biopharma, highlighting his move to Houston's premier oncological ecosystem to maximize patient impact. Through the lens of his team's breakthroughs, Jason reflects on the nature of scientific progress, where the ultimate goal is often proving oneself wrong in order to discover what is truly right. By embracing seemingly impossible challenges and treating immuno-oncology not as an outlier, but as a central pillar of healthcare, Jason illustrates how leaning into difficult work creates a deeply purposeful life that directly restores health to patients and their families.

About Jason: Jason Bock, PhD, is CEO of CTMC, a joint venture between Resilience + MD Anderson Cancer Center. Formed in May 2022 to accelerate patient access to impactful cell therapies by bridging cell therapy development and manufacturing with MD Anderson's clinical trial capabilities. In 2019, Jason was recruited by MD Anderson from Teva Pharmaceuticals to build the Biologics Development group. The group purchased a 60,000 SF facility in the Texas Medical Center and has since formed multiple partnerships with both MD Anderson faculty and early-stage biotech firms to bring their products through the IND process. Previously, Jason was Site Head and VP of Global CMC Biologics in the Specialty R&D Division of Teva Pharmaceuticals. He joined Teva through the acquisition of CoGenesys, a private biotech firm as a spinoff from Human Genome Sciences (HGS), where he worked after completing a PhD at Stanford University in Molecular & Cellular Physiology.

About CTMC: CTMC is a co-development accelerator formed through a joint venture between Resilience and MD Anderson Cancer Center to fast-track the development and manufacturing of next-generation cell therapies for cancer. Located in the heart of the Texas Medical Center, CTMC combines deep expertise in TIL and CAR-T platforms with integrated manufacturing and regulatory capabilities to accelerate the path from discovery to IND. As a true partner, we work side-by-side with cell therapy innovators to advance programs into the clinic faster and chart a clear course to commercial readiness.

Connect with Jason: www.linkedin.com/in/jason-b-bock/

CTMC Website: www.ctmc.com ,

CTMC LinkedIn: www.linkedin.com/company/ctmcplus/

🌐 Wealthing Club: www.wealthing.club